Pharmacokinetics of intravenous levofloxacin administered at 750 milligrams in obese adults

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 7, 2011, Pages 3240-3243

  Cook, Aaron M ^a   Martin, Craig ^a   Adams, Val R ^a   Morehead, R Scott ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LEVOFLOXACIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD ANALYSIS; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ANALYSIS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INFUSION; FEMALE; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; OBESITY; PNEUMONIA; PRIORITY JOURNAL; SINGLE DRUG DOSE; URINARY TRACT INFECTION; WOUND INFECTION;

ADULT; ANTI-BACTERIAL AGENTS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; OBESITY; OFLOXACIN; YOUNG ADULT;

EID: 79959220301     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01680-10     Document Type: Article

References (24)

1. Allard, S., M. Kinzig, G. Boivin, F. Sorgel, and M. LeBel. 1993. Intravenous ciprofloxacin disposition in obesity. Clin. Pharmacol. Ther. 54:368-373.
2. Ambrose, P. G., et al. 2001. Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections. Antimicrob. Agents Chemother. 45:2793-2797.
3. Blouin, R. A., and G. W. Warren. 1999. Pharmacokinetic considerations in obesity. J. Pharm. Sci. 88:1-7.
4. Boucher, B. A., and S. D. Hanes. 1998. Pharmacokinetic alterations after severe head injury. Clin. Pharmacokinet. 35:209-221.
5. Chien, S.-C., et al. 1997. Absence of age and gender effects on the pharmacokinetics of a single 500-milligram oral dose of levofloxacin in healthy subjects. Antimicrob. Agents Chemother. 41:1562-1565.
6. Chien, S.-C., et al. 1997. Pharmacokinetic profile of levofloxacin following once-daily 500-milligram oral or intravenous doses. Antimicrob. Agents Chemother. 41:2256-2260.
7. Chow, A. T., et al. 2001. Safety and pharmacokinetics of multiple 750-milligram doses of intravenous levofloxacin in healthy volunteers. Antimicrob. Agents Chemother. 45:2122-2125.
8. Cook, A. M. 2005. Pharmacokinetic alterations of antimicrobials in the critically ill. J. Pharmacy Pract. 18:75-83. (Pubitemid 40471922)
9. Devine, B. J. 1974. Gentamicin therapy. Drug Intell. Clin. Pharmacy 8:650-655.
10. Djabarouti, S., et al. 2004. Determination of levofloxacin in plasma, bronchoalveolar lavage and bone tissues by high-performance liquid chromatography with ultraviolet detection using a fully automated extraction method. J. Chromatogr. B 799:165-172. (Pubitemid 37500876)
11. Ortho-McNeill, Llc. 2002. Levofloxacin (Levaquin) package insert. Ortho-McNeill, Titusville, NJ.
12. Pea, F., et al. 2003. Pharmacokinetics and pharmacodynamics of intravenous levofloxacin in patients with early-onset ventilator-associated pneumonia. Clin. Pharmacokinet. 42:589-598.
13. Piscitelli, S. C., et al. 1999. Pharmacokinetics and safety of high-dose and extended-interval regimens of levofloxacin in human immunodeficiency virus-infected patients. Antimicrob. Agents Chemother. 43:2323-2327.
14. Power, B. M., A. M. Forbes, P. V. van Heerden, and K. F. Ilett. 1998. Pharmacokinetics of drugs used in critically ill adults. Clin. Pharmacokinet. 34:25-56.
15. Preston, S. L., et al. 1998. Levofloxacin population pharmacookinetics and creation of a demographic model for prediction of individual drug clearance in patients with severe community-acquired infections. Antimicrob. Agents Chemother. 42:1098-1104.
16. Rebuck, J. A., D. N. Fish, and E. Abraham. 2002. Pharmacokinetics of intravenous and oral levofloxacin in critically ill adults in a medical intensive care unit. Pharmacotherapy 22:1216-1225. (Pubitemid 35155075)
17. Reisin, E., F. G. Messerli, H. O. Ventura, and E. D. Frohlich. 1987. Renal haemodynamic studies in obesity hypertension. J. Hypertension 5:397-400.
18. Rodvold, K., and M. Neuhauser. 2001. Pharmacokinetics and pharmacodynamics of fluoroquinolones. Pharmacotherapy 21:233S-252S.
19. Salazar, D. E., and G. B. Corcoran. 1988. Predicting creatinine clearance and renal drug clearance in obese patients from estimated fat-free body mass. Am. J. Med. 84:1053-1060.
20. Schentag, J. J., A. K. Meagher, and A. Forrest. 2003. Fluoroquinolone AUIC break points and the link to bacterial killing rates. 1. In vitro and animal models. Ann. Pharmacother. 37:1287-1298.
21. Spinler, S. A., et al. 1998. Predictive performance of ten equations for estimating creatinine clearance in cardiac patients. Ann. Pharmacother. 32: 1275-1283.
22. Takacs-Novak, K., M. Jozan, I. Hermecz, and G. Szasz. 1992. Lipophilicity of antibacterial fluoroquinolones. Int. J. Pharmaceut. 79:89-96.
23. Weinbren, M. J. 1999. Pharmacokinetics of antibiotics in burn patients. J. Antimicrob. Chemother. 44:319-327.
24. World Health Organization. 31 March 2011, posting date. BMI classification. World Health Organization, Geneva, Switzerland. http://apps.who.int/bmi/index.jsp?introPage=intro-3.html.